Investor interest growing
AI data analytics company Ixico has joined the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to develop and commercialise new treatments for the disease.
The AIM-traded firm has seen investment interest grow thanks to its novel use of AI to understadn brain scans. ADNI as a longitudinal multicentre study, designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD).
The firm announced funding support for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), with two of its scientists to join the ADNI-Private Partner Scientific Board (PPSB).
It said its goals were to detect the disease at the earliest stage possible, and identify ways to track the disease’s progression with biomarkers, as well as to support advances in AD intervention, prevention, and treatment through the application of new diagnostic methods in a pre-competitive environment, and through data sharing to advance the field in AD.
“We are proud to support the ADNI initiative which has made a major contribution to setting the imaging standards in AD research and provides access to important clinical data sets to the global research community,” said chief executive officer Giulio Cerroni.
“ADNI’s purpose is well-aligned with our own goal to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare which will contribute to the advancement of AD research.
“We look forward to engaging with all members of the consortium to contribute to the success of this initiative.”
Ixico said the ADNI-PPSB, convened by the Foundation for the National Institutes of Health (FNIH), facilitated open dialogue around the progress of the ADNI project, as well as new trends with Alzheimer’s disease-related research and development.
“The FNIH is pleased to welcome Ixico to the ADNI-PPSB,” said FNIH associate vice-president Joseph Menetski.
“Ixico’s expertise in data analytics will be a valuable contribution to the role the ADNI-PPSB plays to help develop biomarkers that advance the field of Alzheimer’s disease research.”